Clinical features and real-world pharmacological treatment of severe atopic dermatitis in Colombia: data from an ongoing national registry of patients (RENDAC)

Introduction: The development of an atopic dermatitis (AD) national registry oﬀers a representative view of disease status and its medical management. We sought to characterize clinical features, severity rates and real-world pharmacological treatment in Colombia. Methods: An ongoing National Regist...

Full description

Autores:: Castillo Molina, David
Zakzuk Sierra, Josefina
Moyano Tamara, Lina
Alvis Zakzuk, Nelson Rafael
Fierro Lozada, Jesus Daniel
Alvis Guzman, Nelson
Alvis Zakzuk, Nelson Rafael
Alvis Zakzuk, Nelson J.

Tipo de recurso:: Article of investigation

Fecha de publicación:: 2023

Institución:: Corporación Universidad de la Costa

Repositorio:: REDICUC - Repositorio CUC

Idioma:: eng

Description
Summary:	Introduction: The development of an atopic dermatitis (AD) national registry oﬀers a representative view of disease status and its medical management. We sought to characterize clinical features, severity rates and real-world pharmacological treatment in Colombia. Methods: An ongoing National Registry of Patients with AD in Colombia was created in July-2021. Data from 906 medical records were extracted based on a structured form. Cases were diagnosed by a dermatologist in the outpatient service. Descriptive statistics are reported. Results: Mean age was 22.3 SD±15.6 years-old, half of patients were children (55.3%). Most patients were phototype III (64.5%) and IV (25.7%). SCORAD was reported in 37.4% of records; 39.5% (CI95%:34.2-44.9), 44.3% (38.8-49.7) and 16.2% (12.2–20.3) of cases were classified as mild, moderate, and severe, respectively. SCORAD correlated with age (rho=0.24, p<0.0001) and was similar between sexes. The severe group was in average older (28.1 years SD±23.28) than other groups (mild: 15.2 SD ±15.3, moderate: 18.52 SD ±15.1)) and had significantly higher total IgE levels and eosinophil counts. Most patients received emollients (89%) and topical corticosteroids (57%) for treatment. In the severe group, 40% received systemic immunosuppressants (24%), being methotrexate the most common (22%), 22% received calcineurin-inhibitors and 33% high potency topical corticosteroids. Dupilumab was the only prescribed biologic (15% among severe cases). Conclusions: Frequency and stronger type-2 responses observed in severe AD coincides with expected rates and patterns reported in the literature. Prescription of recommended pharmacological measures for severe DA was lower than expected. Barrier access to medication must be investigated.

Clinical features and real-world pharmacological treatment of severe atopic dermatitis in Colombia: data from an ongoing national registry of patients (RENDAC)

Publicaciones similares